May 28 (Reuters) - Drug developer iTeos Therapeutics ( ITOS )

said on Wednesday it plans to wind down its operations

and explore selling its assets, including experimental cancer

treatments and an obesity program.

Earlier this month, Britain's GSK and iTeos

Therapeutics ( ITOS ) said they have stopped developing an experimental

lung cancer drug, belrestotug, after it failed to stop the

disease from progressing in two studies.